Abstract: Objective To ensure the proportion of bronchiectasis patients with reversible airflow limitation and their responsibility to the bronchodilatator and glucocorticosteroid. Methods The basic pulmonary function, PEF variability measurement and the experiments of bronchodilatation were performed in 48 patients who had been diagnosed for bronchiectasia by HRCT . The positive patients were divided into three groups randomly:group A,the routine treatment group(n=11);group B, the routine treatment +β₂-agonist-inhalation group(n=11);group C, the routine group +β₂-agonist-inhalation + glucocorticosteroid-inhalation group(n=12). Results Among the 48 cases, 31 cases were positive in bronchodilatation experiments ,the PEF variability of 26 cases was higher than 20%,and 34 cases(78.83%) had the reversible airflow limitation. There were 8 cases(72.73%) with the PEF variability lower than 20% in group B while only 5 cases(45.45%) in group A one week after treatment, the difference was significant between group A and group B(P<0.01).The number of days in hospital in group B［(12.18±1.94) d］ was shorter than that in group A［(15.58±2.64) d ］(P<0.01). There were 10 cases (83.33%) with the PEF variability lower than 20% in group C, there was significant difference compared with group B (P<0.01).Compared with group B,the quantity of sputum draining per day and the days in hospital shortened obviously in goups C (P<0.01). Conclusion β₂-agonist and glucocorticosteroid should be inhaled in patients with bronchiectasia and reversible airflow limitation to block the airflow limitation and decrease the quantity of sputum draining,and they are also beneficial to the control of infection.

Key words: reversible airflow limitation, adrenergic beta-agonists, glucocorticoids